Form 4: PAHC CEO Sells Stock Under Pre-Arranged Plan

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC reported sales of Class A Common Stock and conversion of Class B shares under a Rule 10b5-1 plan.

Summary

• Jack Bendheim, through BFI Co., LLC, sold Class A Common Stock on multiple dates in January 2026.
• All reported sales were executed pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• On January 13, 2026, 7,551 shares of Class A Common Stock were sold at a weighted average price of $40.3154.
• On January 14, 2026, 20,000 shares of Class B Common Stock were converted into Class A Common Stock on a one-for-one basis at an exercise price of $0.
• Also on January 14, 2026, 3,258 shares of Class A Common Stock were sold at a weighted average price of $40.4592.
• An additional 393 shares of Class A Common Stock were sold on January 14, 2026, at a weighted average price of $41.1375.
• On January 15, 2026, 2,932 shares of Class A Common Stock were sold at a weighted average price of $40.0233.
• Following these transactions, BFI Co., LLC indirectly holds 44,525 shares of Class A Common Stock and 19,941,034 shares of Class B Common Stock.
• Jack Bendheim directly holds 16,840 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider stock sales and a conversion of Class B to Class A shares by the CEO and an affiliated entity. While insider sales can sometimes be viewed negatively, these transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned divestment strategy rather than a reaction to new, undisclosed negative information. The conversion of Class B to Class A stock is a neutral event, potentially increasing liquidity for the holder.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment strategy rather than an immediate reaction to new, undisclosed negative information.

Negatives

• Sales of Class A Common Stock by a key insider (President and CEO, 10% owner) and an affiliated entity (BFI Co., LLC) could be perceived negatively by some investors, despite being pre-planned.

Future Outlook

NA

Management Comments

• The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Jack Bendheim disclaims beneficial ownership of these securities held by BFI Co., LLC except to the extent of his pecuniary interest therein.

Industry Context

NA

Related Party Transactions

• Jack Bendheim, a director and officer of Phibro Animal Health Corp, exercises voting and dispositive power over BFI Co., LLC, which is also a 10% owner of the Issuer and the entity conducting the reported transactions.

Stakeholder Impact

• Shareholders may perceive a minor negative sentiment due to insider sales, though this is mitigated by the disclosure that the transactions were part of a pre-arranged Rule 10b5-1 plan.

Key Dates

Recommendation

The filing details routine insider transactions, specifically sales of Class A Common Stock by the CEO and an affiliated entity under a pre-arranged Rule 10b5-1 trading plan. While insider sales can sometimes signal a lack of confidence, the existence of a 10b5-1 plan suggests these are planned liquidity events rather than a reaction to new, adverse company developments. The volume of sales is not exceptionally large relative to the insider's total holdings or the company's market capitalization. Therefore, this filing alone does not provide a strong basis for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

PHIBRO ANIMAL HEALTH CORP, PAHC, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, Jack Bendheim, BFI Co., LLC, Class A Common Stock, Class B Common Stock, SEC Filing